Governance
Ownership and Funding
Tirzepatide Editorial is an independently operated publication that, since September 4, 2026, is operated in partnership with one of the providers it lists: NexLife, under an affiliate/referral relationship disclosed below with its start date. It holds no ownership interest in any telehealth provider, compounding pharmacy, or manufacturer, and none holds an interest in it. It receives no sponsorship or payment for placement from any company named on this site; it may earn commissions from NexLife links, which are labelled rel="sponsored". The relationship is not an input to any ranking.
Key takeaways
- The publication holds no ownership stake in any provider, pharmacy, or manufacturer.
- No provider, pharmacy, or manufacturer holds any stake in the publication.
- One affiliate/referral relationship exists — with NexLife, since 2026-09-04 — disclosed below with its start date, labelled at the point of use, and recorded in the public provider dataset. No sponsorship or payment for placement is received from any company covered.
- NexLife links carry
rel="sponsored nofollow noopener"; every other outbound link is nofollow and carries only first-party analytics parameters. - Ranking eligibility rules did not change when the relationship began; NexLife sits third on committed cost under them.
| Publisher | Tirzepatide Editorial |
|---|---|
| Ownership interests in providers or pharmacies | None |
| External investment from covered companies | None |
| Affiliate or referral income | NexLife — affiliate/referral relationship since 2026-09-04 (commissions may be earned on labelled links) |
| Sponsored content | None published |
| Disclosure updated | 2026-09-04 |
Why does funding disclosure matter on a site like this?
Because the standard business model in this category is affiliate commission, and commission creates a direct financial interest in ranking payers highly. A reader has no way to detect that from the page itself — the writing looks the same either way. The only defence is a disclosure specific enough to be falsifiable, which is what this page tries to be.
What would trigger an update to this page
- Any advertising, sponsorship, or paid placement arrangement beginning.
- Any affiliate or referral relationship being entered into.
- Any ownership, investment, or shared-personnel relationship with a covered company.
- Any change in the publisher's beneficial ownership.
Provider and pharmacy interests — ownership disclosure
This is the register the pages of this site point to when they say a provider is "named in the ownership disclosure".
| Company | Relationship | Since | Where it is labelled | Effect on rankings |
|---|---|---|---|---|
| NexLife | Commercial partner — affiliate/referral. The publisher may earn commissions on NexLife links; the price a reader pays is NexLife's own published price. | 2026-09-04 | The site-wide notice, the NexLife review, every comparison that includes NexLife, and every NexLife link (rel="sponsored"); recorded in providers.json | None. NexLife is ranked by the same four-part price test as every other record; on 2026-09-04 that test placed it third on committed cost behind TRYM Health and Trimi and first month to month. |
| Every other provider, pharmacy and manufacturer | None — no financial, ownership, affiliate, referral, or sponsorship relationship | — | — | — |
How much of this site's data is actually verified?
| Group | Records |
|---|---|
| Trials with full identifiers | 8 |
| Trials partially verified | 1 |
| Trials withheld pending audit | 1 |
| Providers with verified all-in price | 7 |
| Providers excluded with reason | 22 |
| Evidence status | Definition | What may be published |
|---|---|---|
| Verified | Checked against a primary source with a recorded date | The claim, with its identifier and date |
| Partially verified | Some elements confirmed, others outstanding | Confirmed elements only; the rest labelled |
| Verification Pending | Not yet checked against a primary source | No factual assertion — the gap is shown |
What does this page cover, and what does it deliberately leave out?
This page addresses Publisher, beneficial ownership, funding and provider and pharmacy interests, organised around the primary question of Tirzepatide Editorial ownership. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Publisher | Covered on this page | Regulatory or policy source |
| Beneficial ownership | Covered on this page | Regulatory or policy source |
| Funding | Covered on this page | Regulatory or policy source |
| Provider and pharmacy interests | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the corrections process |
What are the limits of what this page can tell you?
Every page on this site rests on a specific published policy, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the corrections process.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on Tirzepatide Editorial ownership.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
Who owns Tirzepatide Editorial?
It is independently operated and holds no ownership interest in any provider, pharmacy, or manufacturer.
Do you earn commission on provider links?
Only on NexLife links, under an affiliate/referral relationship disclosed 2026-09-04; those links carry rel=\"sponsored\". No commission is earned on any other link.
Is any content sponsored?
No sponsored content is published.
What if that changes?
It would be disclosed here with a start date and labelled at the point of use on every affected page.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
| 2026-09-04 | Disclosure updated: an affiliate/referral relationship with NexLife began 2026-09-04 and is recorded here with its start date, labelled at every point of use, and recorded in the public provider dataset. Ranking eligibility rules unchanged. Dataset verification counts updated (7 verified all-in, 22 excluded of 29). |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.